MEP13908A - 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations - Google Patents

6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations

Info

Publication number: MEP13908A
Authority: ME; Montenegro
Prior art keywords: treatment; alkenyl; compounds; alkinyl; epoxy
Prior art date: 1999-04-30

Application number

MEP-139/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Ulrich Klar

Wolfgang Schwede

Werner Skuballa

Bernd Buchmann

Jens Hoffmann

Rosemarie Lichtner

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-30

Filing date

2000-05-01

Publication date

2010-06-10

1999-04-30 Priority claimed from DE19921086A external-priority patent/DE19921086A1/de

1999-11-04 Priority claimed from DE19954228A external-priority patent/DE19954228A1/de

2000-03-27 Priority claimed from DE10015836A external-priority patent/DE10015836A1/de

2000-05-01 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2010-06-10 Publication of MEP13908A publication Critical patent/MEP13908A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MEP-139/08A 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations MEP13908A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DE19921086A DE19921086A1 (de)	1999-04-30	1999-04-30	6-Alkenyl- und 6-Alkinyl-Epothilon Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
DE19954228A DE19954228A1 (de)	1999-11-04	1999-11-04	6-Alkenyl-und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
DE10015836A DE10015836A1 (de)	2000-03-27	2000-03-27	6-Alkenyl- und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
PCT/IB2000/000657 WO2000066589A1 (en)	1999-04-30	2000-05-01	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations

Publications (1)

Publication Number	Publication Date
MEP13908A true MEP13908A (en)	2010-06-10

Family

ID=27213767

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-139/08A MEP13908A (en)	1999-04-30	2000-05-01	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations

Country Status (33)

Country	Link
EP (1)	EP1173441B1 (xx)
JP (2)	JP4024003B2 (xx)
KR (1)	KR100721488B1 (xx)
CN (1)	CN100368415C (xx)
AR (1)	AR023792A1 (xx)
AT (1)	ATE440847T1 (xx)
BG (1)	BG65601B1 (xx)
BR (1)	BR0010190A (xx)
CA (2)	CA2371226C (xx)
CY (1)	CY1109768T1 (xx)
CZ (1)	CZ299653B6 (xx)
DE (1)	DE60042821D1 (xx)
DK (1)	DK1173441T3 (xx)
EA (1)	EA011502B1 (xx)
EE (1)	EE05292B1 (xx)
ES (1)	ES2331506T3 (xx)
HK (1)	HK1046681B (xx)
HR (1)	HRP20010892A2 (xx)
HU (1)	HUP0201010A3 (xx)
IL (1)	IL145938A0 (xx)
ME (1)	MEP13908A (xx)
MX (1)	MXPA01011039A (xx)
NO (1)	NO328149B1 (xx)
NZ (1)	NZ514989A (xx)
PE (1)	PE20010116A1 (xx)
PL (1)	PL210762B1 (xx)
PT (1)	PT1173441E (xx)
RS (1)	RS51023B (xx)
SI (1)	SI1173441T1 (xx)
SK (1)	SK286858B6 (xx)
TW (2)	TWI280962B (xx)
WO (1)	WO2000066589A1 (xx)
ZA (1)	ZA200109859B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1186606E (pt)	1995-11-17	2004-08-31	Biotechnolog Forschung Mbh Gbf	Derivados do epotilone sua preparacao e utilizacao
DK0941227T5 (da)	1996-11-18	2009-10-05	Biotechnolog Forschung Gmbh	Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
CA2273083C (en)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6498257B1 (en)	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
US6380395B1 (en)	1998-04-21	2002-04-30	Bristol-Myers Squibb Company	12, 13-cyclopropane epothilone derivatives
US6518421B1 (en) *	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
US6593115B2 (en)	2000-03-24	2003-07-15	Bristol-Myers Squibb Co.	Preparation of epothilone intermediates
DE10020899A1 (de) *	2000-04-20	2001-10-25	Schering Ag	9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
UA75365C2 (en)	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
BRPI0206509B8 (pt)	2001-01-25	2021-05-25	R Pharm Us Operating Llc	processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
MXPA03006485A (es)	2001-01-25	2003-09-22	Bristol Myers Squibb Co	Formulacion parenteral que contiene analogos de epotilona.
NZ526871A (en) *	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
MXPA03007423A (es)	2001-02-20	2003-11-18	Bristol Myers Squibb Co	Derivados de epotilona para tratamiento de tumores refractarios.
EP1385529A4 (en)	2001-02-20	2007-05-09	Bristol Myers Squibb Co	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
IL157443A0 (en)	2001-03-14	2004-03-28	Bristol Myers Squibb Co	Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
EP1392664A4 (en)	2001-06-01	2005-01-26	Bristol Myers Squibb Co	EPOTHILONE DERIVATIVES
EP1340498A1 (en) *	2002-03-01	2003-09-03	Schering Aktiengesellschaft	Use of epothilones in the treatment of brain diseases associated with proliferative processes
DK1483251T3 (da)	2002-03-12	2010-04-12	Bristol Myers Squibb Co	C3-cyano-epothilon-derivater
AU2003218107A1 (en)	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
TW200403994A (en)	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en)	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CN1705662B (zh)	2002-09-23	2011-07-06	布里斯托尔-迈尔斯斯奎布公司	埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构
DE10361794B3 (de) *	2003-12-31	2005-10-06	Schering Ag	Optisch aktive heteroaromatische ß-Hydroxy-Ester und Verfahren zu deren Herstellung sowie deren Verwendung als Zwischenprodukte bei der Epothilon-Totalsynthese
EP1559447A1 (en)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
EP1640004A1 (en) *	2004-09-24	2006-03-29	Schering Aktiengesellschaft	Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) *	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100384419C (zh) *	2005-12-02	2008-04-30	菏泽睿鹰制药集团有限公司	一种埃坡霉素缓释植入组合物及应用
DE102007016046A1 (de)	2007-03-30	2008-10-23	Bayer Schering Pharma Aktiengesellschaft	Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
EP2065054A1 (en)	2007-11-29	2009-06-03	Bayer Schering Pharma Aktiengesellschaft	Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de)	2007-12-10	2009-06-18	Bayer Schering Pharma Aktiengesellschaft	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en)	2007-12-10	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Surface-modified nanoparticles
EP2210584A1 (en)	2009-01-27	2010-07-28	Bayer Schering Pharma Aktiengesellschaft	Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
EP2571525A4 (en)	2010-05-18	2016-04-27	Cerulean Pharma Inc	Compositions and methods for treating autoimmune and other diseases
WO2013092998A1 (en)	2011-12-23	2013-06-27	Innate Pharma	Enzymatic conjugation of antibodies
WO2014009426A2 (en)	2012-07-13	2014-01-16	Innate Pharma	Screening of conjugated antibodies
EP3564259A3 (en)	2012-11-09	2020-02-12	Innate Pharma	Recognition tags for tgase-mediated conjugation
US10611824B2 (en)	2013-03-15	2020-04-07	Innate Pharma	Solid phase TGase-mediated conjugation of antibodies
EP3010547B1 (en)	2013-06-20	2021-04-21	Innate Pharma	Enzymatic conjugation of polypeptides
WO2014202775A1 (en)	2013-06-21	2014-12-24	Innate Pharma	Enzymatic conjugation of polypeptides
WO2019092148A1 (en)	2017-11-10	2019-05-16	Innate Pharma	Antibodies with functionalized glutamine residues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS54115320A (en) *	1978-02-28	1979-09-07	Soda Aromatic	Novel unsaturated keto acid and its manufacture
JP2653663B2 (ja) *	1988-02-15	1997-09-17	財団法人微生物化学研究会	１．３―ジヒドロキシ―８―デセン―５―オンを含む免疫賦活剤及び制癌剤
EP0469480A3 (en) *	1990-08-01	1993-03-10	Hoechst Aktiengesellschaft	Process for stereoselective preparation of 5-substituted delta-lactones and their use
CN1128803C (zh) *	1997-02-25	2003-11-26	生物技术研究有限公司(Gbf)	环氧噻嗪酮b－n－氧化物及其制备方法
US7407975B2 (en) *	1997-08-09	2008-08-05	Bayer Schering Pharma Ag	Epothilone derivatives, method for producing same and their pharmaceutical use

2000
- 2000-04-28 AR ARP000102024A patent/AR023792A1/es active IP Right Grant
- 2000-04-28 PE PE2000000403A patent/PE20010116A1/es not_active Application Discontinuation
- 2000-05-01 WO PCT/IB2000/000657 patent/WO2000066589A1/en not_active Ceased
- 2000-05-01 ME MEP-139/08A patent/MEP13908A/xx unknown
- 2000-05-01 ES ES00922826T patent/ES2331506T3/es not_active Expired - Lifetime
- 2000-05-01 CA CA2371226A patent/CA2371226C/en not_active Expired - Fee Related
- 2000-05-01 IL IL14593800A patent/IL145938A0/xx unknown
- 2000-05-01 HK HK02108204.3A patent/HK1046681B/zh not_active IP Right Cessation
- 2000-05-01 MX MXPA01011039A patent/MXPA01011039A/es active IP Right Grant
- 2000-05-01 EP EP00922826A patent/EP1173441B1/en not_active Expired - Lifetime
- 2000-05-01 SK SK1551-2001A patent/SK286858B6/sk not_active IP Right Cessation
- 2000-05-01 NZ NZ514989A patent/NZ514989A/xx not_active IP Right Cessation
- 2000-05-01 PT PT00922826T patent/PT1173441E/pt unknown
- 2000-05-01 DK DK00922826T patent/DK1173441T3/da active
- 2000-05-01 JP JP2000615619A patent/JP4024003B2/ja not_active Expired - Fee Related
- 2000-05-01 EE EEP200100568A patent/EE05292B1/xx not_active IP Right Cessation
- 2000-05-01 HR HR20010892A patent/HRP20010892A2/xx not_active Application Discontinuation
- 2000-05-01 PL PL351491A patent/PL210762B1/pl not_active IP Right Cessation
- 2000-05-01 SI SI200031044T patent/SI1173441T1/sl unknown
- 2000-05-01 CZ CZ20013885A patent/CZ299653B6/cs not_active IP Right Cessation
- 2000-05-01 RS YUP-776/01A patent/RS51023B/sr unknown
- 2000-05-01 CA CA2651653A patent/CA2651653C/en not_active Expired - Fee Related
- 2000-05-01 CN CNB008069786A patent/CN100368415C/zh not_active Expired - Fee Related
- 2000-05-01 HU HU0201010A patent/HUP0201010A3/hu unknown
- 2000-05-01 EA EA200101025A patent/EA011502B1/ru not_active IP Right Cessation
- 2000-05-01 AT AT00922826T patent/ATE440847T1/de active
- 2000-05-01 DE DE60042821T patent/DE60042821D1/de not_active Expired - Lifetime
- 2000-05-01 BR BR0010190-7A patent/BR0010190A/pt not_active IP Right Cessation
- 2000-05-01 KR KR1020017013840A patent/KR100721488B1/ko not_active Expired - Fee Related
- 2000-05-18 TW TW89108133A patent/TWI280962B/zh not_active IP Right Cessation
- 2000-05-18 TW TW095145399A patent/TWI294292B/zh not_active IP Right Cessation
2001
- 2001-10-26 BG BG106053A patent/BG65601B1/bg unknown
- 2001-10-29 NO NO20015278A patent/NO328149B1/no not_active IP Right Cessation
- 2001-11-29 ZA ZA200109859A patent/ZA200109859B/xx unknown
2007
- 2007-04-11 JP JP2007104224A patent/JP4886578B2/ja not_active Expired - Fee Related
2009
- 2009-11-25 CY CY20091101237T patent/CY1109768T1/el unknown

Also Published As

Publication number	Publication date
CN100368415C (zh)	2008-02-13
MXPA01011039A (es)	2003-06-30
TWI280962B (en)	2007-05-11
PE20010116A1 (es)	2001-02-15
JP2007224038A (ja)	2007-09-06
EP1173441A1 (en)	2002-01-23
CZ20013885A3 (cs)	2002-04-17
NZ514989A (en)	2004-02-27
NO328149B1 (no)	2009-12-21
KR100721488B1 (ko)	2007-05-23
ATE440847T1 (de)	2009-09-15
SK286858B6 (sk)	2009-06-05
CA2371226C (en)	2011-11-29
EE05292B1 (et)	2010-04-15
PL210762B1 (pl)	2012-02-29
EP1173441B1 (en)	2009-08-26
CZ299653B6 (cs)	2008-10-08
NO20015278L (no)	2001-12-21
CA2651653C (en)	2012-02-14
PT1173441E (pt)	2009-11-06
DK1173441T3 (da)	2009-12-07
ZA200109859B (en)	2003-02-28
JP2002543203A (ja)	2002-12-17
BR0010190A (pt)	2002-01-08
CN1349534A (zh)	2002-05-15
SI1173441T1 (sl)	2010-01-29
BG65601B1 (bg)	2009-02-27
BG106053A (en)	2002-05-31
EA011502B1 (ru)	2009-04-28
JP4024003B2 (ja)	2007-12-19
YU77601A (sh)	2005-07-19
IL145938A0 (en)	2002-07-25
HRP20010892A2 (hr)	2008-06-30
CA2651653A1 (en)	2000-11-09
NO20015278D0 (no)	2001-10-29
AR023792A1 (es)	2002-09-04
HUP0201010A3 (en)	2005-02-28
CY1109768T1 (el)	2014-09-10
KR20020005737A (ko)	2002-01-17
PL351491A1 (en)	2003-04-22
RS51023B (sr)	2010-10-31
TW200711679A (en)	2007-04-01
CA2371226A1 (en)	2000-11-09
HK1046681B (zh)	2008-08-29
EE200100568A (et)	2003-02-17
HK1046681A1 (zh)	2003-01-24
SK15512001A3 (sk)	2002-05-09
WO2000066589A1 (en)	2000-11-09
JP4886578B2 (ja)	2012-02-29
EA200101025A1 (ru)	2002-06-27
DE60042821D1 (de)	2009-10-08
TWI294292B (en)	2008-03-11
HUP0201010A2 (en)	2002-08-28
ES2331506T3 (es)	2010-01-07

Publication	Publication Date	Title
MEP13908A (en)	2010-06-10	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
NO952351D0 (no)	1995-06-14	7-halo- og 7 se, og farmasöytiske preparater inneholdende disse
Ayati et al.	2018	Synthesis and biological evaluation of 4-amino-5-cinnamoylthiazoles as chalcone-like anticancer agents
Gu et al.	2012	Synthesis and antitumor activity of α-aminophosphonates containing thiazole [5, 4-b] pyridine moiety
WO2022008627A3 (en)	2022-02-24	Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
WO2007044729A3 (en)	2007-08-09	N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
Qi et al.	2020	Synthesis and biological evaluation of 1-(benzofuran-3-yl)-4-(3, 4, 5-trimethoxyphenyl)-1H-1, 2, 3-triazole derivatives as tubulin polymerization inhibitors
EP0982301A3 (en)	2000-11-08	Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
ATE171170T1 (de)	1998-10-15	7-äther-taxol ähnliche verbindungen antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
BR9910419A (pt)	2001-01-09	Etm-305, etm-204, etm-775, substancialmente puros, processos para tratar leucemia de mamìferos, para tratar carcinoma de pulmão de mamìferos, para tratar adenocarcinoma de cólon de mamìferos, e para tratar melanoma maligno de mamìferos, composição farmacêutica, e, processo para testar o metabolismo citocromo humano cyp3a4 de ecteinascidina 743
Romu et al.	2017	Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors
DE602004023271D1 (de)	2009-11-05	Metastin derivate und ihre verwendung
Choi et al.	2020	Anti-glioma effects of 2-aminothiophene-3-carboxamide derivatives, ANO1 channel blockers
Zhang et al.	2021	A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin
ATE502025T1 (de)	2011-04-15	Arylcarboxamide und ihre verwendung als antitumormittel
AR063417A1 (es)	2009-01-28	Compuestos inhibidores del activador de plasminogeno tipo 1(pai-1)
Malarz et al.	2023	Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations
Das et al.	2007	3-(3, 4, 5-Trimethoxyphenyl)-1-oxo-2-propene: A novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity
CN109206399B (zh)	2020-10-02	三级酰胺微管蛋白聚合抑制剂及其制备方法和应用
Wang et al.	2015	2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic acids as novel selective histone deacetylase-6 inhibitors with antiproliferative activity
Yu et al.	2023	Design, synthesis, and in vitro anticancer activity of novel chrysin derivatives
CN109206362A (zh)	2019-01-15	含芳香杂环类微管蛋白聚合抑制剂及其合成方法和应用
DE60205470D1 (de)	2005-09-15	Analoge von 4-beta-1''-[(2''-(substitutierte-benzoyl)anilin]-podophyllotoxin zur verwendung als antikrebs-agentia
Islim et al.	2025	Exploring the anticancer potential of nitrated N-substituted-4-hydroxy-2-quinolone-3-carboxamides: synthesis, biological assessment, and computational analysis
Song et al.	2013	Design, synthesis and biological evaluation of novel aliphatic amido/sulfonamido-quaternary ammonium salts as antitumor agents